TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04246125

Intervention type: PROCEDURE
Intervention: Interventional radiology : skin dose measurements
Description: Therapeutic interventional radiology procedure for the following anatomical regions:~* cerebral (neuroradiology)~* thoracic (cardiology, lungs)~* abdominal~Assessment of peak skin dose and dose mapping with use of Gafchromic film dosimeter and the estimation of the absorbed dose to the skin with use of RDM software program.
Study: NCT02051738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole - fasted state (Treatment A)
Description: Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole - fasted state (Treatment A)
Description: Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole - fed state (Treatment B)
Description: Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fed condition.
Study: NCT04176406

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: excitatory 5Hz rTMS will be used
Study: NCT02051738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole - fed state (Treatment B)
Description: Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fed condition.
Study: NCT04653389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Injection
Description: Sintilimab Injection is used as neoadjuvant therapy and adjuvant therapy.
Study: NCT04176406

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: excitatory 5Hz rTMS will be used

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
Study: NCT05214703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold therapy application
Description: cold therapy
Study: NCT05145881

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low dose probiotics
Description: Taking 1 package of low dose probiotic powder (B. breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) twice daily before meals (BIDAC).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal dose probiotics
Description: Taking 1 package of normal dose probiotic powder (B. breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) twice daily before meals (BIDAC).
Study: NCT02316665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure
Description: continuous positive airway pressure treatment during three months with adherence recording
Study: NCT04653389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE
Description: The first TACE and Sintilimab Injection will be initiated simultaneously.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Use Cone Beam computor tomography(CBCT) locates the lession before the therapy.
Study: NCT02215616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.
Study: NCT00519610

Intervention type: OTHER
Intervention: Chart Review
Description: Patients' charts will be reviewed for relevant medical information.
Study: NCT05920200

Intervention type: PROCEDURE
Intervention: open non-mesh hernia repair
Description: A groin and femoral hernia non-mesh repair. An umbilical hernia non-mesh repair. A ventral and incisional hernia non-mesh repair.
Study: NCT02316665

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-continuous positive airway pressure
Description: Sham-continuous positive airway pressure during three months with adherence recording
Study: NCT03696030

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Given HER2-CAR T cells via intraventricular administration
Study: NCT00396435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neorecormon
Description: Administration SC one a week in patients randomized in group A Administration SC if Hb below 10.5 g/dl in group B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neorecormon
Description: Administration SC one a week in patients randomized in group A Administration SC if Hb below 10.5 g/dl in group B
Study: NCT04278950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: For the PVP-I group, the final concentration of available iodine in the solution will be 0.01%, (from diluting 10% PVP-I solution), as previously demonstrated to be below ciliotoxic levels of 1.25% and greater than 0.01% which is the lower limit of active potency.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The placebo will be 2.5mL of saline with brown food coloring.
Study: NCT05920200

Intervention type: PROCEDURE
Intervention: open non-mesh hernia repair
Description: A groin and femoral hernia non-mesh repair. An umbilical hernia non-mesh repair. A ventral and incisional hernia non-mesh repair.

Intervention type: PROCEDURE
Intervention: open non-mesh hernia repair
Description: A groin and femoral hernia non-mesh repair. An umbilical hernia non-mesh repair. A ventral and incisional hernia non-mesh repair.

Intervention type: PROCEDURE
Intervention: open mesh hernia repair
Description: A groin and femoral hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures for Lichtenstein. Self-fixating mesh is also possible.~An umbilical, ventral, incisional hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures.

Intervention type: PROCEDURE
Intervention: open mesh hernia repair
Description: A groin and femoral hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures for Lichtenstein. Self-fixating mesh is also possible.~An umbilical, ventral, incisional hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures.

Intervention type: PROCEDURE
Intervention: open mesh hernia repair
Description: A groin and femoral hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures for Lichtenstein. Self-fixating mesh is also possible.~An umbilical, ventral, incisional hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures.
Study: NCT04365777

Intervention type: OTHER
Intervention: OAA/S=5
Description: Prior to anesthesia induciton, EEG signatures will be recorded at Observer's Assessment of Alertness/Sedation (OAA/S) score of 5 (awake, eye-close state) for few minutes.

Intervention type: OTHER
Intervention: OAA/S=3
Description: Given sedative anesthetics (propofol, midazolam or dexmetomidine), EEG signatures will be recorded after reaching steady state of OAA/S=3 (responds only after name called loudly and/or repeatedly) for few minutes.

Intervention type: OTHER
Intervention: OAA/S=1
Description: Increasing drug concentration, EEG signatures will be recorded after reaching steady state of OAA/S=1 (does not respond to noxious stimuli) for few minutes.
Study: NCT04245956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measure of hemodynamic indices in a stenosed coronary artery using a pressure wire
Description: The intervention consists of measuring a series of hemodynamic indices in a stenosed coronary using a pressure wire, immediately before and after transcatheter mitral valve repair using the percutaneous edge-to-edge MitraClip system in patients with severe mitral insufficiency and concomitant intermediate coronary artery stenosis.
Study: NCT00599378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation Intentions-based telephone counseling
Description: Implementation Intentions-based telephone counseling
Study: NCT01749917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Exercise program An brief exercise session including proprioceptive and dexterity activities
Study: NCT00426868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct injection of ADRCs into the Left Ventricle
Description: Dose escalation
Study: NCT01749917

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: Active upper limb range of movement exercises for 15 minutes.
Study: NCT00968799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraoperative intraperitoneal chemotherapy
Description: Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreduction
Description: Surgical removal of tumor nodules~including resection of organs infested with tumor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is applied as chemotherapy during surgery
Study: NCT04682769

Intervention type: OTHER
Intervention: Other
Description: Patients with Coronary Heart Disease and Depressive Disorder are receiving routine treatment by their physician.
Study: NCT00426868

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Direct injection of placebo into the Left Ventricle
Study: NCT01413243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova
Description: Trichuris suis ova 2500 eggs every 2 weeks
Study: NCT01126411

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immunoadsorption / immunglobulin substitution
Description: Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
Study: NCT01413243

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trichuris suis ova
Description: Trichuris suis ova 2500 eggs every 2 weeks
Study: NCT05002985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking group led by a community organizer
Description: Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
Study: NCT00460655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1358820
Description: botulinum toxin type A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03544905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYH33 for tablet
Description: 1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)
Study: NCT04265248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: The subjects will wear the Virtual Reality Headset with a mobile phone inserted into it with the applications Full Dive VR and VR Ocean Aquarium 3D.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The subjects will perform evidence-based exercises for the neck.
Study: NCT05920200

Intervention type: PROCEDURE
Intervention: MIS hernia repair
Description: A groin and femoral minimal invasive hernia repair (TAPP, eTEP). The mesh is affixed with tack/no-fixation. Self-fixation mesh is also possible.~An umbilical, ventral, incisional minimal invasive hernia repair (eTEP, IPOM,). The mesh is affixed with tack and no-fixation .

Intervention type: PROCEDURE
Intervention: MIS hernia repair
Description: A groin and femoral minimal invasive hernia repair (TAPP, eTEP). The mesh is affixed with tack/no-fixation. Self-fixation mesh is also possible.~An umbilical, ventral, incisional minimal invasive hernia repair (eTEP, IPOM,). The mesh is affixed with tack and no-fixation .

Intervention type: PROCEDURE
Intervention: MIS hernia repair
Description: A groin and femoral minimal invasive hernia repair (TAPP, eTEP). The mesh is affixed with tack/no-fixation. Self-fixation mesh is also possible.~An umbilical, ventral, incisional minimal invasive hernia repair (eTEP, IPOM,). The mesh is affixed with tack and no-fixation .
Study: NCT03329573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine IR tablets A
Description: Paroxetine IR tablets A will be the investigational drug. These are film coated tablets with unit dose strength of 20 milligrams (mg) and will be administered via oral route. These tablets will be manufactured in GSKT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine IR tablets A
Description: Paroxetine IR tablets A will be the investigational drug. These are film coated tablets with unit dose strength of 20 milligrams (mg) and will be administered via oral route. These tablets will be manufactured in GSKT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine IR tablets B
Description: Paroxetine IR tablets B will be the reference drug. These are film coated tablets with unit dose strength of 20 mg and will be administered via oral route. These tablets will be manufactured in Mississauga.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine IR tablets B
Description: Paroxetine IR tablets B will be the reference drug. These are film coated tablets with unit dose strength of 20 mg and will be administered via oral route. These tablets will be manufactured in Mississauga.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine IR tablets B
Description: Paroxetine IR tablets B will be the reference drug. These are film coated tablets with unit dose strength of 20 mg and will be administered via oral route. These tablets will be manufactured in Mississauga.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine IR tablets B
Description: Paroxetine IR tablets B will be the reference drug. These are film coated tablets with unit dose strength of 20 mg and will be administered via oral route. These tablets will be manufactured in Mississauga.
Study: NCT02914470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbplatin, cyclophophamide, atezolizumab
Study: NCT01311479

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulation Therapy
Description: Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction.~Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulation Therapy
Description: Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction.~Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment.
Study: NCT03589872

Intervention type: DIAGNOSTIC_TEST
Intervention: Fine motor dexterity test, nine hole peg test
Description: The nine hole peg test will be performed under two different task (1)single task, (2)adding a cognitive task
Study: NCT02318745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Informed Family Treatment for Adolescents
Description: Family Therapy, Psycho-educational Modules, Individual therapy sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Treatment
Description: Cognitive Behavior Therapy, Interpersonal psychotherapy, social skills training, anger control training, problem solving skills, assertiveness training, and the Empty chair technique from Gestalt therapy
Study: NCT03926260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ctDNA analysis
Description: blood sample at Baseline, 3weeks, 9 weeks after treatment, at progression if applicable
Study: NCT01574937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: 28 day cycle
Study: NCT04834050

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadriceps femoris isometric home-based exercise
Description: All 3 groups of participants were given 4-week (5 days/week) quadriceps-hamstring isometric home-based exercise training for their both knees. Exercises were performed (with maximal effort for 10 seconds) at a rate of 20 repetitions per day. Training was performed at outpatient clinic for 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadriceps femoris isometric home-based exercise
Description: All 3 groups of participants were given 4-week (5 days/week) quadriceps-hamstring isometric home-based exercise training for their both knees. Exercises were performed (with maximal effort for 10 seconds) at a rate of 20 repetitions per day. Training was performed at outpatient clinic for 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadriceps femoris isometric home-based exercise
Description: All 3 groups of participants were given 4-week (5 days/week) quadriceps-hamstring isometric home-based exercise training for their both knees. Exercises were performed (with maximal effort for 10 seconds) at a rate of 20 repetitions per day. Training was performed at outpatient clinic for 30 minutes.
Study: NCT03514238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Aerobic Exercise (HIIT)
Description: Cycling at 50-55% heart rate reserve for 5 minutes followed by 2 minutes of cycling at 85-90% heart rate reserve consecutively for a total of 35 minutes.~Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Aerobic Exercise (HIIT)
Description: Cycling at 50-55% heart rate reserve for 5 minutes followed by 2 minutes of cycling at 85-90% heart rate reserve consecutively for a total of 35 minutes.~Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min).
Study: NCT01380678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional injection of bevacizumab
Description: single dose of 2 mg of bevacizumab intralesional injection on pterygium Combination of topical antazoline and tetrahydrozoline four times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical antihistamine and vasoconstrictor
Description: combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
Study: NCT03514238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous Moderate Aerobic Exercise (MOD)
Description: 35 minutes of cycling at 50-55% heart rate reserve. Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous Moderate Aerobic Exercise (MOD)
Description: 35 minutes of cycling at 50-55% heart rate reserve. Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Sitting Condition (C)
Description: Blood draws matched for exercise time will be taken while participant remains seated for 35 minutes (0min, 7min, 14min, 21min, 28min, 35min).
Study: NCT04422782

Intervention type: OTHER
Group type: OTHER
Intervention: For each routine sample, an additional tube will be collected to measure the osmotic pressure in the blood and urine
Description: Interventional research protocol involving the human person category 2 at risk and minimal constraints
Study: NCT00586352

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stable isotope infusions
Description: Subjects receive stable isotope infusions through an IV for about 3 hours. The dosage is based on weight.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stable isotope infusions
Description: Subjects receive stable isotope infusions through an IV for about 3 hours. The dosage is based on weight.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stable isotope infusions
Description: Subjects receive stable isotope infusions through an IV for about 3 hours. The dosage is based on weight.
Study: NCT01268332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-medicated Intravaginal Ring
Description: Cured silicone elastomer composed of an elastomer base, normal propylorthosilicate, and titanium dioxide. The ring will not contain an active pharmaceutical ingredient.
Study: NCT03285308

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injected subcutaneously twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relamorelin
Description: Relamorelin 10 micrograms (μg) injected subcutaneously twice daily.
Study: NCT04190069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral interventions/modifications
Description: UPMC Prescription for Wellness is an innovative physician/provider prescribed coaching and feedback program that improves patient engagement and outcomes in healthy behaviors; self-care of chronic disease and condition management; and shared decision-making. The resources available through this program are offered via a telephonic health coach, online or through a digital intervention based on the participant's convenience.